Syncom Formulations
14.65
-0.19(-1.28%)
Market Cap₹1,377.10 Cr
PE Ratio22.19
IndustryHealthcare
Company Performance:
1D-1.28%
1M-5.18%
6M-24.52%
1Y-27.11%
5Y+80.86%
View Company Insightsright
More news about Syncom Formulations
19May 25
Syncom Formulations Reports Impressive Q4 Financial Results with Substantial Growth
Syncom Formulations announced impressive Q4 financial results, with revenue soaring 104% year-over-year to ₹1,500.00 crore. Net profit surged 159% to ₹175.00 crore, while EBITDA nearly doubled to ₹175.00 crore. Despite strong overall performance, EBITDA margin slightly decreased to 11.67% from 12.02% in the previous year.
Syncom Formulations
14.65
-0.19
(-1.28%)
1 Year Returns:-27.11%
Industry Peers
Sun Pharmaceutical
1,737.00
(-1.08%)
Divis Laboratories
6,496.50
(+0.31%)
Torrent Pharmaceuticals
3,834.30
(+0.37%)
Cipla
1,496.30
(-0.29%)
Dr Reddys Laboratories
1,265.80
(-1.38%)
Lupin
2,107.00
(-0.31%)
Zydus Life Science
917.80
(-1.08%)
Mankind Pharma
2,193.30
(-1.63%)
Aurobindo Pharma
1,211.40
(-0.54%)
Alkem Laboratories
5,566.00
(-0.55%)